ClinicalTrials.gg

Program

HRS-1893

A development code. Also written as “HRS-1893 Tablet”, “Test formulation of HRS-1893 tablet” and “Reference formulation of HRS-1893 tablet”.

In Jiangsu HengRui Medicine's pipeline, Myosin. Its studies are mostly in Cardiomyopathy, Hypertrophic · Cardiomyopathies · Heart Failure, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Jun 6, 202512 company-led studies, 5 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine125 open or runningphase 3since Jun 6, 2025May 18, 2023Mar 2027phase 2 · NCT07269717
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-1893, phase 3, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 18, 2023First study: phase 1 study in Cardiomyopathy, HypertrophicFirst studyNCT05879523 · 76 enrolled · China
  2. Apr 3, 2024Phase 1 study in Cardiomyopathy, HypertrophicNCT06354556 · 14 enrolled · China
  3. Jun 28, 2024Phase 2 study in Cardiomyopathy, HypertrophicNCT06516068 · 42 enrolled · China
  4. Jan 9, 2025Phase 1 study in Cardiomyopathy, HypertrophicNCT06775834 · 24 enrolled · China
  5. Feb 4, 2025Phase 2 study in Non-obstructive Hypertrophic CardiomyopathyNCT06816251 · 84 enrolled · China
  6. May 20, 2025Early phase 1 study in Cardiomyopathy, HypertrophicNCT07033455 · 20 enrolled · Australia
  7. Jun 6, 2025Phase 3 study in Cardiomyopathy, HypertrophicNCT07021976 · 228 enrolled · China
  8. Jun 6, 2025Phase 2 study in Cardiomyopathy, HypertrophicNCT07021963 · 300 planned · China
  9. Nov 26, 2025Phase 1 study in CardiomyopathiesNCT07272330 · 38 enrolled · China
  10. Nov 26, 2025Phase 2 study in Heart Failure With Preserved Ejection FractionNCT07269717 · 48 planned · China
  11. Mar 11, 2026Phase 1 study in CardiomyopathiesNCT07479641 · 58 enrolled · China
  12. Jun 15, 2026Phase 1 study in CardiomyopathiesNCT07656779 · 6 planned · China

Ahead

  1. Mar 2027Primary completion: phase 2 study in Heart Failure With Preserved Ejection FractionNCT07269717
  2. Dec 2027Primary completion: phase 2 study in Cardiomyopathy, HypertrophicNCT07021963

TargetBeta

“Myosin”the company's pipeline, read by Claude · source

Other programs on MYH7

ProgramCompanyFurthest phaseStudies
mavacamtenruleBristol-Myers Squibbphase 420
omecamtiv mecarbilruleCytokineticsphase 316
danicamtivruleBristol-Myers Squibbphase 37

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07656779Cardiomyopathies · China1Not yet recruitingJul 20266
NCT07479641Cardiomyopathies · China1CompletedSep 14, 202658
NCT07272330Cardiomyopathies · China1CompletedMar 21, 202638
NCT07269717Heart Failure With Preserved Ejection Fraction · China2RecruitingMar 202748
NCT07021976Cardiomyopathy, Hypertrophic · China3Active, not recruitingSep 2026228
NCT07021963Cardiomyopathy, Hypertrophic · China2RecruitingDec 2027300
NCT07033455Cardiomyopathy, Hypertrophic · AustraliaEarly 1CompletedSep 5, 202520
NCT06816251Non-obstructive Hypertrophic Cardiomyopathy · China2CompletedNov 18, 202584
NCT06775834Cardiomyopathy, Hypertrophic · China1CompletedJul 23, 202524
NCT06516068Cardiomyopathy, Hypertrophic · China2Active, not recruitingNov 18, 202442
NCT06354556Cardiomyopathy, Hypertrophic · China1CompletedMay 20, 202414
NCT05879523Cardiomyopathy, Hypertrophic · China1CompletedMar 21, 202476

How it is read

Names in the registry

  • “HRS-1893”, 5 entries
  • “HRS-1893 Tablet”, 2 entries
  • “Test formulation of HRS-1893 tablet”, 1 entry
  • “Reference formulation of HRS-1893 tablet”, 1 entry
  • “HRS-1893 Tablets”, 1 entry

Codes read as this program: HRS1893.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.